nach oben

Acta Neuropathologica

Erschienen in:

01.04.2008 | Original Paper

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

verfasst von: Kurt A. Jellinger, Johannes Attems

Erschienen in: Acta Neuropathologica | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Whereas the prevalence and impact of vascular pathology in Alzheimer diease (AD) are well established, the role of vascular and Alzheimer pathologies in the progression of neurodegeneration and cognitive impairment in Parkinson disease (PD) is under discussion. A retrospective clinico-pathologic study of 100 patients with autopsy proven PD (including 44 cases with dementia/PDD) and 20 cases of dementia with Lewy bodies (DLB) confirmed essential clinical (duration of illness, Mini-Mental State Examination/MMSE, age at death) and morphologic differences between these groups; Lewy body Braak scores and Alzheimer pathologies (neuritic Braak stage, cortical Aβ plaque load, and generalized cerebral amyloid angiopathy or CAA) were significantly higher/more severe in DLB and PDD than in PD without dementia. Duration of illness showed no association to any of the examined pathologic parameters, while there was a moderate association between LB scores and neuritic Braak stages, the latter significantly increasing with age. Significant association between cerebrovascular lesions and neuritic Braak stage was seen in PDD but not in PD subjects without dementia. These data suggest an influence of Alzheimer-related lesions on the progression of the neurodegenerative process and, in particular, on cognitive decline in both PDD and DLB. On the other hand, both these factors in PD and DLB appear to be largely independent from coexistent vascular pathology, except in cases with severe cerebrovascular lesions or those related to neuritic AD pathology. Assessment of ApoE genotype in a small number of cases showed no significant differences in the severity of Aβ plaque load and CAA except for much lower intensities in non-demented ε3/3 patients. Despite increasing evidence suggesting synergistic reactions between α-synuclein (αSyn), tau and Aβ-peptides, the major protein markers of both AD and Lewy body diseases, and of both vascular pathology and AD, the molecular background and pathophysiological impact of these pathologies on the progression of neurodegeneration and development of cognitive decline in PD await further elucidation.

Adler CH, Grover AC, Sabbagh MN, Caviness JN, Connor DJ, Beach TG (2006) Clinical and pathologic findings in PD with LRRK2 mutations: 2 cases with mild cognitive impairment and small amplitude myoclonus. Mov Disord 21(Suppl 15):S538

Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) Alpha-synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888:287–296PubMedCrossRef

Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110:345–359PubMedCrossRef

Attems J, Jellinger KA, Lintner F (2005) Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropathol 110:222–231PubMedCrossRef

Attems J, Quass M, Jellinger KA, Lintner F (2007) Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci 257:49–55PubMedCrossRef

Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer’s disease. Neurol Res 26:573–578PubMedCrossRef

Bancher C, Egensperger R, Kosel S, Jellinger K, Graeber MB (1997) Low prevalence of apolipoprotein E epsilon 4 allele in the neurofibrillary tangle predominant form of senile dementia. Acta Neuropathol 94:403–409PubMedCrossRef

Barrachina M, Dalfo E, Puig B, Vidal N, Freixes M, Castano E, Ferrer I (2005) Amyloid-beta deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor. Neurochem Int 46:253–260PubMedCrossRef

Bertrand E, Lewandowska E, Pasennik E, Stepien T, Szpak GM, Dymecki J, Wierzba-Bobrowicz T (2007) Cerebral amyloid angiopathy in idiopathic Parkinson’s disease. Acta Neuropathol (in press)

10.

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedCrossRef

11.

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef

12.

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134PubMedCrossRef

13.

Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMed

14.

Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K (2006) Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21:2042–2051PubMedCrossRef

15.

Burton EJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT (2004) Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain 127:791–800PubMedCrossRef

16.

Burton EJ, McKeith IG, Burn DJ, Firbank MJ, O’Brien JT (2006) Progression of white matter hyperintensities in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia: a comparison with normal aging. Am J Geriatr Psychiatry 14:842–849PubMedCrossRef

17.

Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA (2003) Parkinson’s disease is associated with hippocampal atrophy. Mov Disord 18:784–790PubMedCrossRef

18.

de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33:1152–1162CrossRef

19.

Del Ser T, Hachinski V, Merskey H, Munoz DG (2001) Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 15:31–44PubMedCrossRef

20.

Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, Delacourte A (2006) Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65:278–288PubMed

21.

Desai BS, Monahan AJ, Carvey PM, Hendey B (2007) Blood–brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transplant 16:285–299PubMed

22.

Dickson DW (2000) Alzheimer–Parkinson disease overlap: neuropathology. In: Clark CM, Trojanowski JQ (eds) Neurodegenerative dementias. McGraw-Hill, New York, pp 247–259

23.

Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 20:2302–2312PubMedCrossRef

24.

Galasko D, Salmon D (2000) The Alzheimer–Parkinson’s disease connection. In: Clark CM, Trojanowski JQ (eds) Neurodegenerative dementias. McGraw-Hill, New York, pp 229–246

25.

Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449–458PubMedCrossRef

26.

Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. Neurology 67:1605–1611PubMedCrossRef

27.

Geddes JW (2005) Alpha-synuclein: a potent inducer of tau pathology. Exp Neurol 192:244–250PubMedCrossRef

28.

Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636–640PubMedCrossRef

29.

Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59:315–322PubMedCrossRef

30.

Greenberg SM, Gurol ME, Rosand J, Smith EE (2004) Amyloid angiopathy-related vascular cognitive impairment. Stroke 35:2616–2619PubMedCrossRef

31.

Guerini F, Frisoni GB, Bellwald C, Rossi R, Bellelli G, Trabucchi M (2004) Subcortical vascular lesions predict functional recovery after rehabilitation in patients with l-dopa refractory parkinsonism. J Am Geriatr Soc 52:252–256PubMedCrossRef

32.

Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378–384PubMedCrossRef

33.

Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M, Rice V, Butters N, Alford M (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8PubMed

34.

Hansen LA (1997) The Lewy body variant of Alzheimer disease. J Neural Transm Suppl 51:83–93PubMed

35.

Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP (2005) The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson’s disease. Acta Neurol Scand 112:386–390PubMedCrossRef

36.

Hughes TA, Ross HF, Mindham RH, Spokes EG (2004) Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 110:118–123PubMedCrossRef

37.

Iseki E, Marui W, Kosaka K, Ueda K (1999) Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 265:9–12PubMedCrossRef

38.

Iseki E, Togo T, Suzuki K, Katsuse O, Marui W, de Silva R, Lees A, Yamamoto T, Kosaka K (2003) Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 105:265–270PubMed

39.

Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389–397PubMed

40.

Jellinger KA (1996) Parkinsonism due to Binswanger’s subcortical arteriosclerotic encephalopathy. Mov Disord 11:461–462PubMedCrossRef

41.

Jellinger KA (2003) Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study. J Neural Transm 110:771–778PubMedCrossRef

42.

Jellinger KA (2003) Prevalence of cerebrovascular lesions in Parkinson’s disease. A postmortem study. Acta Neuropathol 105:415–419PubMed

43.

Jellinger KA, Attems J (2003) Incidence of cerebrovascular lesions in Alzheimer’s disease: a postmortem study. Acta Neuropathol 105:14–17PubMed

44.

Jellinger KA, Mitter-Ferstl E (2003) The impact of cerebrovascular lesions in Alzheimer disease––a comparative autopsy study. J Neurol 250:1050–1055PubMedCrossRef

45.

Jellinger KA, Seppi K, Wenning GK (2003) Neuropathologic changes in Parkinson disease with late onset of dementia. Arch Neurol 60:452–453 author reply 453–454CrossRef

46.

Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235PubMedCrossRef

47.

Jellinger KA, Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 229–230:37–41PubMedCrossRef

48.

Jellinger KA (2006) The morphological basis of mental dysfunction in Parkinson’s disease. J Neurol Sci 248:167–172PubMedCrossRef

49.

Jellinger KA, Attems J (2006) Prevalence and impact of cerebrovascular pathology in Alzheimer’s disease and parkinsonism. Acta Neurol Scand 114:38–46PubMedCrossRef

50.

Jellinger KA (2007) The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113:349–388PubMedCrossRef

51.

Jellinger KA, Attems J (2007) Neuropathological evaluation of mixed dementia. J Neurol Sci 257:80–87PubMedCrossRef

52.

Jellinger KA, Attems J (2008) Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm. doi:10.1007/S00702-00007.00856.00708

53.

Jendroska K, Lees AJ, Poewe W, Daniel SE (1996) Amyloid beta-peptide and the dementia of Parkinson’s disease. Mov Disord 11:647–653PubMedCrossRef

54.

Junque C, Ramirez-Ruiz B, Tolosa E, Summerfield C, Marti MJ, Pastor P, Gomez-Anson B, Mercader JM (2005) Amygdalar and hippocampal MRI volumetric reductions in Parkinson’s disease with dementia. Mov Disord 20:540–544PubMedCrossRef

55.

Kallhoff V, Peethumnongsin E, Zheng H (2007) Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer’s disease. Mol Neurodegener 2:6PubMedCrossRef

56.

Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ (2007) Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 130:2123–2128PubMedCrossRef

57.

Kumaran R, Kingsbury A, Coulter I, Lashley T, Williams D, de Silva R, Mann D, Revesz T, Lees A, Bandopadhyay R (2007) DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders. Neurobiol Dis 28:122–132PubMedCrossRef

58.

Lashley T, Holton JL, Gray E, Kirkham K, O’Sullivan SS, Hilbig A, Wood NW, Lees AJ, Revesz T (2008) Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson’s disease patients. Acta Neuropathol. doi:10.1007/s00401-00007-00336-00400

59.

Lee VM, Trojanowski JQ (2006) Mechanisms of Parkinson’s disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52:33–38PubMedCrossRef

60.

Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487–1491PubMedCrossRef

61.

Lippa CF (2004) Synaptophysin immunoreactivity in Pick’s disease: comparison with Alzheimer’s disease and dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 19:341–344PubMedCrossRef

62.

Lippa SM, Lippa CF, Mori H (2005) Alpha-Synuclein aggregation in pathological aging and Alzheimer’s disease: the impact of beta-amyloid plaque level. Am J Alzheimers Dis Other Demen 20:315–318PubMedCrossRef

63.

Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease. Neurochem Res 31:1153–1162PubMedCrossRef

64.

Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K (2003) The role of alpha-synuclein in Parkinson’s disease: insights from animal models. Nat Rev Neurosci 4:727–738PubMedCrossRef

65.

Mark MH, Sage JI, Walters AS, Duvoisin RC, Miller DC (1995) Binswanger’s disease presenting as levodopa-responsive parkinsonism: clinicopathologic study of three cases. Mov Disord 10:450–454PubMedCrossRef

66.

Marshall GA, Shchelchkov E, Kaufer DI, Ivanco LS, Bohnen NI (2006) White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. Acta Neurol Scand 113:87–91PubMedCrossRef

67.

Marti MJ, Tolosa E, de la Cerda A (2007) Dementia in Parkinson’s disease. J Neurol 254(Suppl):41–48CrossRef

68.

Marui W, Iseki E, Ueda K, Kosaka K (2000) Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease. J Neurol Sci 174:81–84PubMedCrossRef

69.

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L (2001) Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci USA 98:12245–12250PubMedCrossRef

70.

Mastaglia FL, Masters CL, Beyreuther K, Kakulas BA (1989) Deposition of Alzheimer’s disease amyloid (A4) protein in the cerebral cortex in Parkinson’s disease. Prog Clin Biol Res 317:475–484PubMed

71.

Mastaglia FL, Johnsen RD, Kakulas BA (2002) Prevalence of stroke in Parkinson’s disease: a postmortem study. Mov Disord 17:772–774PubMedCrossRef

72.

Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA (2003) Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease. Mov Disord 18:81–86PubMedCrossRef

73.

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMed

74.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRef

75.

Mikolaenko I, Pletnikova O, Kawas CH, O’Brien R, Resnick SM, Crain B, Troncoso JC (2005) Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 64:156–162PubMed

76.

Mrak RE, Griffin WS (2007) Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol 66:683–686PubMed

77.

Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC, Dagher A, Ito K (2005) Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64:224–229PubMed

78.

Neumann M, Muller V, Gorner K, Kretzschmar HA, Haass C, Kahle PJ (2004) Pathological properties of the Parkinson’s disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease. Acta Neuropathol 107:489–496PubMedCrossRef

79.

Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ (1996) The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer’s disease and Lewy body variant. Neurology 47:190–196PubMed

80.

Olichney JM, Ellis RJ, Katzman R, Sabbagh MN, Hansen L (1997) Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer’s disease. Ann N Y Acad Sci 826:493–497PubMedCrossRef

81.

Papapetropoulos S, Lieberman A, Gonzalez J, Mash DC (2005) Can Alzheimer’s type pathology influence the clinical phenotype of Parkinson’s disease? Acta Neurol Scand 111:353–359PubMedCrossRef

82.

Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367PubMed

83.

Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26:1183–1192PubMedCrossRef

84.

Popescu A, Lippa CF, Lee VM, Trojanowski JQ (2004) Lewy bodies in the amygdala: increase of a-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 61:1915–1919PubMedCrossRef

85.

Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN (1996) Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol 148:2083–2095PubMed

86.

Reitz C, Trenkwalder C, Kretzschmar K, Roesler A, Eckardstein VA, Berger K (2006) Relation of cerebral small-vessel disease and brain atrophy to mild Parkinsonism in the elderly. Mov Disord 21(11):1914–1919PubMedCrossRef

87.

Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235–246PubMed

88.

Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S (2003) Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62:644–654PubMed

89.

Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayama S (2004) Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 63:742–749PubMed

90.

Schmidt ML, Martin JA, Lee VM, Trojanowski JQ (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy body disorders. Acta Neuropathol 91:475–481PubMedCrossRef

91.

Shao CY, Crary JF, Rao C, Sacktor TC, Mirra SS (2006) Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies. J Neuropathol Exp Neurol 65:327–335PubMedCrossRef

92.

Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59:733–748PubMed

93.

Thanvi B, Lo N, Robinson T (2005) Vascular parkinsonism––an important cause of parkinsonism in older people. Age Ageing 34:114–119PubMedCrossRef

94.

Thomas A, Ballard C, Kenny RA, O’Brien J, Oakley A, Kalaria R (2005) Correlation of entorhinal amyloid with memory in Alzheimer’s and vascular but not Lewy body dementia. Dement Geriatr Cogn Disord 19:57–60PubMedCrossRef

95.

Tian J, Shi J, Mann DM (2004) Cerebral amyloid angiopathy and dementia. Panminerva Med 46:253–264PubMed

96.

Trembath D, Ervin JF, Broom L, Szymanski M, Welsh-Bohmer K, Pieper C, Hulette CM (2007) The distribution of cerebrovascular amyloid in Alzheimer’s disease varies with ApoE genotype. Acta Neuropathol 113:23–31PubMedCrossRef

97.

Trembath Y, Rosenberg C, Ervin JF, Schmechel DE, Gaskell P, Pericak-Vance M, Vance J, Hulette CM (2003) Lewy body pathology is a frequent co-pathology in familial Alzheimer’s disease. Acta Neuropathol 105:484–488PubMed

98.

Uchikado H, Lin WL, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65:685–697PubMed

99.

Wenning GK, Jellinger KA (2005) The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 18:357–362PubMedCrossRef

100.

Wirths O, Bayer TA (2003) Alpha-synuclein, Abeta and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 27:103–108PubMedCrossRef

101.

Wu E, Lipton RB, Dickson DW (1992) Amyloid angiopathy in diffuse Lewy body disease. Neurology 42:2131–2135PubMed

102.

Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607PubMedCrossRef

103.

Zlokovic BV (2004) Clearing amyloid through the blood–brain barrier. J Neurochem 89:807–811PubMedCrossRef

Titel: Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
verfasst von: Kurt A. Jellinger
Johannes Attems
Publikationsdatum: 01.04.2008
Verlag: Springer-Verlag
Erschienen in: Acta Neuropathologica / Ausgabe 4/2008
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-008-0347-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Animal models of Parkinson’s disease progression

Clarifying the pathological progression of Parkinson’s disease

Kurt Jellinger Prize 2008 for Outstanding Scientific Writing in Neuropathology

Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

α-Synuclein pathology in the neostriatum in Parkinson’s disease

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie